Impact of fdg pet for staging of ewing sarcomas and primitive neuroectodermal tumours

Nuclear Medicine Communications

Volumn 27, Issue 1, 2006, Pages 17-24

  Györke, Tamás ^a   Zajic, Thomas ^b   Lange, Alexander ^c   Schäfer, Oliver ^c   Moser, Ernst ^c   Makó, Ernõ ^c   Brink, Ingo ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Department of Diagnostic Radiology and Oncotherapy ^*  (Hungary)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Bone scintigraphy; Ewing sarcoma; Positron emission tomography; Primitive neuroectodermal tumour

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; 2,3 DICARBOXYPROPANE 1,1 DIPHOSPHONATE TECHNETIUM TC 99M;

ADOLESCENT; ADULT; ARTICLE; BONE TUMOR; CHILD; EVALUATION; EWING SARCOMA; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEUROECTODERM TUMOR; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; BONE SCINTISCANNING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN TISSUE; INTERMETHOD COMPARISON; METASTASIS; OSTEOMYELITIS; RADIODIAGNOSIS;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEUROECTODERMAL TUMORS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SARCOMA, EWING'S; SENSITIVITY AND SPECIFICITY;

EID: 33645215499     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000186608.12895.69     Document Type: Article

References (41)

1. Dehdashti F, Siegel BA, Griffeth LK, Fusselman MJ, Trask DD, McGuire AH, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology 1996; 200:243-247.
2. Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, Bielack S, Jurgens H, et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001; 12:479-486.
3. Franzius C, Daldrup-Link HE, Wagner-Bohn A, Sciuk J, Heindel WL, Jurgens H, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002; 13:157-160.
4. Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27:1305-1311.
5. Garcia R, Kim EE, Wong FC, Korkmaz M, Wong WH, Yang DJ, et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37:1476-1479.
6. Kole AC, Nieweg OE, Hoekstra HJ, van Horn JR, Koops HS, Vaalburg W. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39:810-815.
7. Nieweg OE, Pruim J, van Ginkel RJ, Hoekstra HJ, Paans AM, Molenaar WM, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996; 37:257-261.
8. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med 1998; 26:599-605.
9. Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 2004; 30:83-101.
10. Lucas JD, O'Doherty MJ, Wong CH, Bingham JB, McKee PH, Fletcher CDM, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg (Br) 1998; 80-B:441-447.
11. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508-1512.
12. 18F]FDG. J Comput Assist Tomogr 1990; 14:960-962.
13. Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DA, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215-1220.
14. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998; 39:250-254.
15. Folpe AL, Lyles RH, Sprouse JT, Conrad 3rd EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000; 6:1279-1287.
16. Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29:181-186.
17. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30.
18. Lucas JD, O'Doherty MJ, Cronin BF, Marsden PK, Lodge MA, McKee PH, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999; 86:550-556.
19. Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000; 41:1695-1701.
20. 18fluorine-FDG PET as an aid to preoperative planning. J Bone Joint Surg 2000; 82:760-767.
21. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25:874-881.
22. Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996; 37:1438-1444.
23. Nair N, Ali A, Green AA, Lamonica G, Alibazoglu H, Alibazoglu B, et al. Response of osteosarcoma to chemotherapy: Evaluation with F-18 FDG-PET scans. Clin Positron Imaging 2000; 3:79-83.
24. Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40:1637-1643.
25. Franzius C, Schulte M, Hillmann A, Winkelmann W, Jurgens H, Bockisch A, et al. Clinical value of positron emission tomography (PET) in the diagnosis of bone and soft tissue tumors. 3rd Interdisciplinary Consensus Conference ‘PET in Oncology’: results of the Bone and Soft Tissue Study Group. Chirurgie 2001; 72:1071-1077 [in German].
26. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331:294-299.
27. Schmidt D, Herrmann C, Jurgens H, Harms D. Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. A report from the Kiel Pediatric Tumor Registry. Cancer 1991; 68:2251-2259.
28. 18F]-fluoro-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235-238.
29. Mix M, Nitzsche EU. PISAC: a post-injection method for segmented attenuation correction in whole body PET. J Nucl Med 1999; 40(Suppl):297P.
30. Piepsz A, Hahn K, Roca I, Ciofetta G, Toth G, Gordon I, et al. A radiopharmaceuticals schedule for imaging in paediatrics. Eur J Nucl Med 1990; 17:127-129.
31. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35:1773-1782.
32. Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, et al. FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med 2003; 30:BP115-BP124.
33. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma 2000; 39:543-553.
34. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115:272-278.
35. Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998; 9:275-281.
36. Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jurgens H, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol 2001; 177:229-236.
37. Guhlmann A, Brecht-Krauss D, Suger G, Glatting G, Kotzerke J, Kinzl L, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749-754.
38. Durbin M, Randall RL, James M, Sudilovsky D, Zoger S. Ewing's sarcoma masquerading as osteomyelitis. Clin Orthop 1998; 357:176-185.
39. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312.
40. Kurata T, Oguri T, Isobe T, Ishioka S, Yamakido M. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res 1999; 90:1238-1243.
41. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979; 3:299-308.